Icon

HELIDAC (nda050719)- (262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG)

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE CASPER PHARMA LLC
262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG
No No
Expired Expired
None None
None No
The components of the HELIDAC Therapy (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer).
1 0 0
Total Other Developers None
Drugs with Suitability No
262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.